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Introduction
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Standard therapy includes 
surgery, radiation, temozolomide chemotherapy, and, more recently, tumor-treating fields (1). Recur-
rence, on average, occurs 6 months after maximal therapy (2). GBM stem cells (GSCs), also known as 
tumor-propagating cells or tumor-initiating cells (3), may be one reason for inevitable recurrence, as they 
are highly resistant to radiation and chemotherapy (4–6). GSCs were first isolated using an antibody against 
the cell-surface protein CD133 (Prominin-1) (7). CD133hi cells have clonogenic self-renewal capacity and 
efficiently engraft and form intracranial tumors in immunocompromised mice (8, 9). Although sorting by 
CD133 enriches for GSC function, CD133lo cells can also exhibit clonogenic self-renewal and asymmetric 
cell division, albeit less efficiently (10, 11). Alternative single-surface markers such as CD15 (SSEA-1), 
CD44, α6 integrin, and A2B5 may also enrich for the GSC state (12–16). The literature has used the term 
GSC with varying definitions. We use it here as synonymous with a stem cell marker–bearing GBM cell. 
GSCs tend to be enriched in serum-free media conditions, often referred to as stem cell media condi-
tions. It remains unknown how GSC populations defined by single-surface markers compare with each 
other, in terms of  intracellular signaling and function and whether expression of  different combinations 
of  these markers is associated with differences in the probability of  tumor-forming capacity. More broadly, 
it remains unknown whether all GSCs are alike or have their own hierarchy of  function. These issues are 
important for how we study GBM in vitro and in animal models and understand intratumor and intertu-
mor heterogeneity and treatment resistance.
Most patients with glioblastoma (GBM) die within 2 years. A major therapeutic goal is to target 
GBM stem cells (GSCs), a subpopulation of cells that contribute to treatment resistance and 
recurrence. Since their discovery in 2003, GSCs have been isolated using single-surface markers, 
such as CD15, CD44, CD133, and α6 integrin. It remains unknown how these single-surface marker–
defined GSC populations compare with each other in terms of signaling and function and whether 
expression of different combinations of these markers is associated with different functional 
capacity. Using mass cytometry and fresh operating room specimens, we found 15 distinct 
GSC subpopulations in patients, and they differed in their MEK/ERK, WNT, and AKT pathway 
activation status. Once in culture, some subpopulations were lost and previously undetectable 
ones materialized. GSCs that highly expressed all 4 surface markers had the greatest self-renewal 
capacity, WNT inhibitor sensitivity, and in vivo tumorigenicity. This work highlights the potential 
signaling and phenotypic diversity of GSCs. Larger patient sample sizes and antibody panels are 
required to confirm these findings.
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Mass cytometry is a quantitative analytical technique whereby single cells labeled with antibodies 
tagged with rare earth metals are ionized and analyzed by time-of-flight mass spectrometry. This largely 
overcomes the spectral overlap typical of  standard flow cytometry, which limits the number of  observations 
possible on a given cell. As such, mass cytometry theoretically enables the use of  up to 100 analysis chan-
nels, with over 50 currently available heavy metal isotopes to study (17, 18).
We used mass cytometry to evaluate the intracellular states associated with 4 commonly used GSC 
surface markers, CD15, CD44, CD133, and α6 integrin. We measured normal neural stem cell–associated 
intracellular markers that have also been implicated in GSC proliferation, migration, and tumorigenesis, 
e.g., Sox2 (19–21), Musashi (22–24), Nanog (25), and Nestin (26) (7, 8, 12). We also probed core devel-
opmental pathways that are often activated in GSCs and for which targeted therapies are available, such 
as PI3K/AKT (27), MEK/ERK (28), JAK/STAT (29), WNT/β-catenin (30, 31), NF-κB (32, 33), and 
MAPK/P38 (34); their downstream effectors; and cancer-associated markers (Table 1).
To study GBM by mass cytometry, patient samples were quickly dissociated into single cells and fixed 
prior to analysis to avoid loss of  phenotypic markers and cell populations (35, 36). We herein report that 
GSC subpopulations differ in signaling, self-renewal potential, and in vivo tumorigenicity depending on 
which surface markers are used to isolate them. We also report that the composition of  the overall GSC 
population shifts in culture, compared with fresh isolates.
Results
Mass cytometric analysis of  fresh patient samples identified a heterogeneous distribution of  GSC subpopulations 
between patients. We obtained fresh tumor samples from the operating room of  6 patients at the time of  
GBM diagnosis (Table 2). We dissociated tumors into single-cell suspension within 30 minutes after 
tissue acquisition. We obtained an average of  1.35 × 104 live cells per mg of  tissue, and 3 × 106 via-
ble cells were immediately labeled for mass cytometry. To identify GSC subpopulations based on stem 
cell–surface marker state, using 4 GSC markers and their combinations, we considered 15 theoretical 
states, assuming each cell can have high or low expression of  each marker, and 1 non-GSC state (low 
expression for all 4 surface markers). For positive and negative controls for cell-surface and intracellular 
GSC markers, we used the patient-derived GSC line 0308 cultured in Neurobasal media supplemented 
with growth factors and cultured in DMEM media containing 10% FBS for 6 weeks, respectively. GSCs 
grown in the presence of  FBS are phenotypically distinct from cells grown in serum-free media (37), 
and FBS-containing media reduced the expression of  all 4 surface markers (Supplemental Figure 1; sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.128456DS1). 
From the 6 patient specimens, we identified all 16 possible states (Figure 1). The entire population of  
GSCs, as defined as high expression of  at least one GSC cell-surface marker, comprised an average of  
29.6% (range from 22.2% to 37%) of  live cells analyzed. We observed a heterogeneous distribution of  
GSC subpopulations between patients. The range of  high expression for each individual marker was 
3.3%–9.3% CD15, 3.1%–53% CD44, 6.6%–19% CD133, and 2.0%–16.2% α6 integrin. Some populations 
were rare and represented less than 1% of  the entire GSC population, e.g., CD15hiCD44hiCD133hi and 
CD15hiCD44hiCD133hiα6 integrin
hi (Figure 1 and Supplemental Table 1).
We also assessed the expression of  the intracellular neural stem cell–associated proteins Sox2, 
Musashi-1, Nestin, and Nanog. We observed that all 4 intracellular markers were expressed in GSCs and 
non-GSCs (Figure 2). We also found that 14%–50% of  the cells expressing any of  the 4 neural stem cell–
associated intracellular markers also expressed a single GSC cell-surface marker (Figure 2). Conversely, 
compared with non-GSCs, not all GSC subpopulations had high levels of  expression of  one of  these neural 
stem cell–associated intracellular markers (Supplemental Figure 2).
Compared with non-GSCs, fresh GSC subpopulations differed in MEK/ERK, WNT, and AKT pathway activa-
tion and had increased WNT and NF-κB activation. To determine the activation level of  intracellular pathways, 
we used mass cytometry with a panel of  20 antibodies (Table 1). Activation of  the PI3K/AKT, MEK/
ERK, JAK/STAT, NF-κB, and MAPK/P38 pathways was determined by increased phosphorylation of  
AKT (pAKT), ERK (pERK), STAT3 (pSTAT3), P65 (pP65), and P38 (pP38), respectively. Activation of  
the WNT pathway was determined by increased expression of  non–phospho-β-catenin. We found that the 
quadruple-high subpopulation, CD15hiCD44hiCD133hiα6 integrin
hi, had high expression of  pERK and non–
phospho-β-catenin compared with cells with low expression of  surface markers (Figure 3A). In addition, 
the subpopulation CD44hiCD133hiα6 integrin
hi also had consistently high expression of  phospho-ERK and 
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non–phospho-β-catenin among all 6 patients. In contrast, CD15hi and CD15hiCD133hi subpopulations had 
consistently low expression of  pAKT (Figure 3A).
GSCs as a group had significantly greater WNT activation (P < 0.01 patients 1–4 and 6) compared with 
cells lacking expression of  all of  the GSC surface markers (quadruple low; Figure 3B). We also tested wheth-
er the presence of  greater numbers of  stem cell–surface markers is associated with greater WNT activation. 
Combining our patient data and collapsing the subpopulations into single, double, triple, or quadruple-high 
states from each patient sample, and correcting for multiple hypothesis testing, we found that increased 
numbers of  surface markers were associated with increased expression of  non–phospho-β-catenin (Figure 
3C; P values in Supplemental Table 2), a transcription factor that is activated when a Wnt ligand binds to 
the Frizzled and LRP6 coreceptors (38). The quadruple-high subpopulation, CD15hi CD44hi CD133hi α6 
integrinhi, had the highest protein expression of  non–phospho-β-catenin in samples from patients 1, 2, 3, 5, 
and 6. In patient 4, which lacked the quadruple-high subpopulation, the subpopulations with high expres-
sion of  any 3 surface markers had the greatest abundance of  non–phospho-β-catenin. Additionally, GSCs 
as a group had increased expression of  pP65 compared with non-GSCs, a surrogate of  NF-κB pathway 
activation (33) (Figure 3B; P < 0.01 patients 1–4 and 6). Myeloid cells in the tumor microenvironment did 
not likely skew our interpretation (Supplemental Figure 3).
Short term culture was associated with both loss and gain of  GSC subpopulations. We were only able to derive 
one GSC line from our 6 patient specimens (patient 4, GSC line B142). We test whether GSC subpopulation 
compositions were perturbed by culture conditions. Using FACS (Supplemental Figure 4), we observed that 
although the initial specimen contained 14 GSC states, after short-term culture (14 passages), only 10 sub-
populations were detected (Figure 4A). Interestingly, although we failed to detect 5 GSC subpopulations that 
had existed in the fresh sample, 2 subpopulations were detectable in the cultured sample (Figure 4, A and B).
GSC subpopulations in short-term and long-term culture had different self-renewal capacities, depending on the 
cell-surface markers used to define them. Using B142, we measured the relative rates of  clonogenic self-renewal 
of  each sorted GSC population using the extreme limiting dilution assay (ELDA) (39, 40). Clonogenic 
potential ranged from 0.4% to 6.3% (Figure 4C). The cells expressing high levels of  CD44 and CD133 only 
(CD44hiCD133hi) and all 4 markers (CD15hiCD44hiCD133hiα6 integrin
hi) had the greatest degree of  self-re-
newal capacity, with clonogenic potential of  6.3% and 4.9%, respectively (Figure 4C; CD44hi, P < 0.01; 
Table 1. Antibodies used in mass cytometry analysis
Antigen Conjugate Clone Catalog no. Supplier
CD15 144Nd W6D3 3164001B Fluidigm
CD44 166Er BJ18 3166001B Fluidigm
CD133 170Er 293C3 130-090-851 Miltenyi
α6 Integrin 164Dy G0H3 3164006B Fluidigm
Non–phospho-β-catenin 165Ho D13A1 3165027A Fluidigm
pAKT [S473] 152Sm D9E 3152005A Fluidigm
pS6 [S235/S236] 172Yb N7-548 3172008A Fluidigm
pERK1/2 [T202/Y204] 171Yb D13.14.4E 3171010A Fluidigm
p-P38 [T180/Y182] 156Gd D3F9 3156002A Fluidigm
pStat3 [Y705] 158Gd 4/P-Stat3 3158005A Fluidigm
pNF-κB p65 [S529] 160Gd REA348 130-095-212 Miltenyi
p4E-BP1 [T37/T46] 149Sm 236B4 3149005A Fluidigm
SOX2 150Nd O30-678 3150019B Fluidigm
Nanog 169Tm N31-355 3169014A Fluidigm
Musashi-1 155Gd 14H1 3155013B Fluidigm
Nestin 146Nd 196908 3146015 Fluidigm
p53 143Nd DO-7 3150024A Fluidigm
MYC 176Yb 9E10 3176012B Fluidigm
p21 159Tb 12D1 3159026A Fluidigm
Ki-67 168Er Ki-67 3168001B Fluidigm
CD45A 089Y HI30 3089003B Fluidigm
AUsed only in samples from patients 5 and 6.
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CD133hi, P < 0.01; α6 integrin
hi, P = 0.0179; CD44hiα6 integrin
hi, P < 0.01; CD133hiα6 integrin
hi, P = 0.0194; 
CD15hiCD44hiα6 integrin
hi, P < 0.01; CD44hiCD133hiα6 integrin
hi, P = 0.0417).
Similarly, we identified from 3 patient-derived GSC lines in long-term culture (Table 3) 13 of  the 16 
possible states (Supplemental Figure 5). Clonogenic potential as measured by ELDA ranged from 0.3% 
to 12.3% in TS667 GSCs (Figure 5A); 0.3% to 46.3% in 0308 GSCs (Figure 5B); and 1.4 % to 9.7% in 
MGG8 GSCs (Figure 5C). For TS667 and 0308, the quadruple-high subpopulation had the greatest 
degree of  in vitro self-renewal capacity (Figure 5, A and B) (TS667, CD15hi, P < 0.01; CD44hi, P < 
0.01; CD15hiCD133hi, P = 0.0437; CD15hiα6 integrin
hi, P = 0.0104; CD44hiα6 integrin
hi, P < 0.01; 0308, 
CD15hiα6 integrin
hi, P < 0.01; CD44hiα6 integrin
hi, P < 0.01; CD133hiα6 integrin
hi, P < 0.01; CD15hiC-
D44hiα6 integrin
hi, P < 0.01; CD15hiCD133hiα6 integrin
hi, P < 0.01). For MGG8, both the α6 integrin 
high and the quadruple-high subpopulations had the greatest extent of  clonogenic potential (Figure 5C) 
(CD15hi, P < 0.01; CD44hi, P < 0.01; CD133hi, P < 0.01; CD15hiα6 integrin
hi, P < 0.01; CD44hiCD133hi, 
P < 0.01; CD133hiα6 integrin
hi, P < 0.01; CD15hiCD44hiCD133hi, P < 0.01; CD15hiCD44hiα6 integrin
hi, P 
< 0.01; CD15hiCD133hiα6 integrin
hi, P < 0.01; CD44hiCD133hiα6 integrin
hi, P < 0.01).
GSC subpopulations differed in intracellular pathway activation states and downstream effectors in vitro, depend-
ing on the cell-surface markers used to define them. For mass cytometry studies of  GSC subpopulations, we used 
Table 2. Patient information
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Survival time (days) 317 728 527 182 109 (alive) 131 (alive)
Presentation
60-year-old left-




handed man who 
presented with 1 
month of headaches 
and blurry vision
82-year-old right-
handed woman who 









handed woman who 








agraphia for 3 weeks
Tumor location
Left medial 
temporal and into 
corpus callosum
Left temporal Left posterior frontal Right temporal Left temporal Right parietal
Tumor genetics
MGMT promoter  
not methylated





























of exons encoding 
kinase domain
EGR amplification




PTEN loss of 
function
MDM4 amplification
NF1 loss of function MLL3 spice site 
mutation




SPTA1 mutation FRS2 amplification EGFR mutation 
del intron 13–1, del 
intron 1–7
Equivocal CDK6 and 
HGF amplifications
QKI truncation in 
exon6
Pertinent negatives No EGFR, IDH1, PDGFRA mutations
No IDH1, PDGFRA 
mutations
No IDH1, PDGFRA 
mutations
No IDH1, PDGFRA 
mutations
No IDH1, PDGFRA 
mutations
No IDH1 mutation 
by IHC
Microsatellite status Stable Stable Stable Stable Stable Unknown
Tumor mutational 
burden Low Low Low Low Low (3 mut/MB) Unknown
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antibodies against the same 4 cell-surface markers above. We also assessed signal activation using antibod-
ies against pAKT, pERK, pSTAT3, non–phospho-β-catenin, pP65 (NF-κB), and pP38. In TS667 GSCs, the 
quadruple-high subpopulation, CD15hiCD44hiCD133hiα6integrin
hi, had the greatest average activation of  
all 6 pathways studied (Figure 6A). In particular, similar to the fresh operating room GSC specimens, this 
subpopulation of  TS667 had the highest abundance of  pERK and non–phospho-β-catenin compared with 
other GSC subpopulations (Figure 6A). In 0308 GSCs, the CD44hiCD133hi subpopulation presented the 
strongest activation of  the PI3K/AKT, WNT/β-catenin, NF-kB, and MAPK/P38 pathways (Figure 6B). 
In MGG8 GSCs, the CD15hiCD44hiα6 integrin
hi subpopulation had the strongest activation of  the PI3K/
AKT, WNT/β-catenin, and NF-kB pathways (Figure 6C).
To determine whether GSC subpopulations may differ in cell biological processes, we assayed 
markers of  cell proliferation (Ki-67) (41–43) and RNA translation (p4E-BP1, pS6) (44, 45). In TS667 
GSCs, expression of  Ki-67, pS6 and p4E-BP1 were the highest in the quadruple-high subpopulation 
Figure 1. All GSC subpopulations exist in patients. Pie charts demonstrate the percentage of each GSC subpopulation relative to the total number of cells 
analyzed from each patient sample. The percentage of cells that highly express at least one of CD15, CD44, CD133, or α6 integrin is indicated under the 
patient number. GSC, glioblastoma stem cell.
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(Figure 7A). In 0308 GSCs, the CD44hiCD133hi subpopulation had high expression of  Ki-67, pS6, 
and p4E-BP1 (Figure 7B). In MGG8 GSCs, the triple-high, CD15hiCD44hiα6 integrin 
hi, and the qua-
druple-high, CD15hiCD44hiCD133hiα6 integrin
hi, subpopulations had greatest expression of  Ki-67, pS6, 
and p4E-BP1 (Figure 7C). In summary, in standard culture conditions, high expression of  a single-cell 
surface marker was inadequate to identify the state with greatest self-renewal capacity or greatest intra-
cellular pathways activation.
Given that we observe heterogenous activation of  WNT signaling in patient samples and cell lines, 
we next investigate whether GSC subpopulations have differential sensitivity to WNT inhibition. We 
treated cells with the canonical WNT inhibitor XAV939, which increases degradation of  β-catenin and 
decreases β-catenin–mediated transcription (46). We found that the quadruple-high cells were more sen-
sitive to WNT inhibition than α6 integrin
hi cells in TS667 (CD15hi, CD44hi, and CD133hi, nonsignificant; 
Figure 2. Intracellular neural stem cell–associated proteins are expressed in GSCs and non-GSCs. For each indicated intracellular protein, all cells that 
highly express it total to 100%. The subpopulation contribution to this total is indicated. GSCs, glioblastoma stem cells.
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α6 integrin
hi, P = 0.042), CD15hi, CD44hi, and CD133hi cells in 0308 (CD15hi, CD44hi, and CD133hi, P 
< 0.01; α6 integrin
hi, nonsignificant). We found no significant sensitivity to WNT inhibition in MGG8 
GSC subpopulations (Figure 8).
GSC subpopulations differed in their in vivo tumorigenicity. We used a murine intracranial implantation assay 
to examine whether distinct GSC-associated cell-surface marker profiles are associated with differences in 
in vivo tumorigenesis. Using the MGG8 patient GSC line, we used magnetic beads and FACS to enrich 
and isolate subpopulations based on single-surface markers or high expression of  all 4 markers, and com-
pared them with unsorted cells grown in standard GSC-enriching media conditions. Upon implantation 
into the right frontal lobes of  NCG female immunodeficient mice (NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl), we 
followed mice for survival. The quadruple-high subpopulation had the shortest median survival (20.5 days) 
compared with unsorted (median beyond 100 days, P < 0.01). The cells expressing single markers were also 
Figure 3. GSC subpopulations have differential activation of MEK/ERK, WNT, AKT, and NF-κB pathways. (A) Side panels indicate the expression level 
(high, black; low, gray) of the cell-surface markers that define each subpopulation. Across each patient, the indicated protein in each subpopulation is 
shown; heatmaps indicate fold protein expression relative to non-GSCs. Six intracellular pathways (pAKT, pERK, pSTAT3, non–phospho-β-catenin, pP65, 
and pP38) and three intracellular downstream effectors (Ki-67, p4E-BP1, and pS6) were examined. (B) Expression of non–phospho-β-catenin and pP65 in 
GSCs and non-GSCs, on log scale. Kruskal-Wallis with Mann-Whitney U post hoc tests were used, *P < 0.05 vs. non-GSCs. (C) Expression of non–phos-
pho-β-catenin in GSCs grouped by the number of highly expressed surface markers, on log scale. Kruskal-Wallis with Bonferroni’s post hoc tests were 
used; *P < 0.05. GSC, glioblastoma stem cell.
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more aggressive than the unsorted cells: α6 integrin (29.5 days, P < 0.01), CD15 (33.5 days, P < 0.01), CD133 
(43 days, P < 0.01), or CD44 (53 days, P = 0.0802) (Figure 9). Mice implanted with CD133hi (P = 0.0183) or 
CD44hi (P = 0.0209) cells had significantly longer survival than quadruple high as well. Together, these data 
suggest that even when cells are grown in stem cell–promoting media conditions, upon implantation these 
unsorted cells had different growth dynamics in vivo than surface marker–enriched cells. Additionally, there 
may be important in vivo differences between quadruple-high cells and specific subpopulations.
Discussion
The CD15hiCD44hiCD133hi α6 integrin
hi subpopulation was enriched for GSC characteristics. We used mass cytom-
etry to characterize the single-cell protein signaling status of  fresh GSCs. This may prove a valuable addi-
tion to single-cell RNA sequencing in understanding GBM biology and heterogeneity. Single-cell RNA 
sequencing can detect rare GSC populations cells and transcriptional activation of  pathways (47); however, 
it does not render a clear observation of  proteomic intracellular signaling. A multiomic approach can better 
clarify GBM biology and heterogeneity.
Because GSCs may be one reason for inevitable recurrence in GBM, single-cell analysis of  pro-
tein states in heterogeneous GSCs may lead to GSC subpopulation–specific therapies. Bulk proteomic 
Figure 4. GSC populations are lost and gained in culture, and CD15hiCD44hiCD133hi α6 integrinhi (quadruple high) cells 
and CD44hiCD133hi cells derived from patient 4 are the most clonogenic. (A) B142 GSCs were derived from patient 
4. Black indicates the presence of the indicated GSC subpopulation; hash pattern indicates its absence. (B) Pie chart 
indicates the percentage of each GSC subpopulation relative to the total B142 population. (C) Clonogenic self-renewal 
for B142 cell line was assessed by extreme limiting dilution analysis (24, 5, and 1 cells per well; 12–18 replicates per 
dilution). The experiment was repeated 3 times, and the results are shown as mean ± SEM. ANOVA with Tukey’s post 
hoc tests were used to assess the significance of differences between each GSC subpopulation. *P < 0.05 vs. quadru-
ple-high. GSC, glioblastoma stem cell.
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analysis using mass spectrometry with patient-derived GSCs can identify differential expression of  pro-
teins and phosphoproteins. Recent mass spectrometry studies found increased protein phosphoryla-
tion, including the histone methyltransferase enhancer of  zeste homolog 2 and the cell motility protein 
hyaluronan-mediated motility receptor in GSCs compared with neural stem cells from the adult human 
brain (48); TGF-β receptor type 2 in GSCs grown with EGF compared with GSCs grown in the pres-
ence of  serum (49); and activation of  S6K pathways in GBM cells compared with non-GSCs (50). Pro-
teomics studies also associated the single amino acid variants S1559T in phosphatidylinositol-3,4,5-tri-
sphosphate dependent Rac exchange factor 1 and V632A in dynein axonemal assembly factor 5 with 
increased risk of  GBM (51). However, these studies were done in bulk cells and did not allow single-cell 
resolution to identify GSC subpopulations and analyze their proteome. In its ability to enable single-cell 
analysis of  the signaling status of  proteins, mass cytometry adds granular context to bulk transcription-
al and proteomic analysis.
Individual or double positive expression of  cell-surface markers has been widely studied (9, 14, 16, 52), 
but multidimensional stem cell–surface marker studies in GBM are rare and have only been performed 
in vitro (53). By using 4 stem cell–surface markers, we found 15 states of  GSCs exist, each with different 
levels of  activation of  core signaling pathways in both patient samples and cell lines. We found that the 
quadruple-high subpopulation, CD15hiCD44hiCD133hiα6 integrin
hi, had the highest capacity for clonogenic 
self-renewal in 2 of  4 GSC lines in culture (Figures 4 and 5). α6 integrin 
hi and CD44hiCD133hi also had high 
clonogenic capacity, but other subpopulations did not follow a clear pattern of  surface marker combination 
and clonogenic potential.
The quadruple-high cells exhibited the highest activation of  MEK and WNT pathways among GSC 
subpopulations in patient samples 1, 2, and 3 and patient samples 1, 2, 3, 5, and 6, respectively, and in the 
long-term cultured TS667 GSCs. To put this in context, it is known that GSC sphere formation requires 
ERK activation (28), and GSC tumorigenic capacity and self-renewal requires both the WNT activation 
and the crosstalk between MEK/ERK and PI3K/AKT (28, 54). EGFR is commonly amplified or mutat-
ed in GBM (28) and MEK/ERK and PI3K/AKT are downstream of  EGF signaling (55). Activation of  
MEK/ERK and PI3K pathways suppresses apoptosis (56) and cellular differentiation (28) while promoting 
cellular proliferation (57). In addition, depletion of  the Wnt secretion protein Evi/Gpr177 in both glioma 
and GSCs decreases cell proliferation and apoptosis (54). Taken together, increased MEK/ERK and WNT 
activation in the quadruple-high subpopulation suggests that inhibiting these pathways may be clinically 
useful in targeting this highly clonogenic subset of  glioma cells.
Table 3. Patient characterization for TS667, 0308, and MGG8 cell lines
GSC line (ref.) Patient Description
TS667 (78) 69-year-old man






0308 (37) 37-year-old man
Homozygous deletion of INK4a/ARF locus (chromosome 9)
Loss of chromosome 10q
Trisomy of chromosomes 7 and 20
Partial trisomy of chromosome 19
Translocation t(10;21)
Local amplification of EGFR (approximately 6 copies of EGFR/cell)
PTEN mutation (nonsense mutation at amino acid 76)





Homozygous deletion of CDKN2A/B
AFurther details of this patient are restricted by the institutional requirements.
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In vivo, the quadruple-high GSCs were the most aggressive, along with the α6 integrin
hi. Our results 
do not support a clear linear relationship between number of  surface markers present and tumorigenicity. 
For example, CD15hiα6 integrin
hi was not particularly more clonogenic than CD15hiCD133hiα6 integrin
hi 
or CD15hi was not more clonogenic than CD15hiCD133hi. GSCs may represent a plastic state that can be 
adopted by cancer cells in response to environmental cues rather than a clonal entity defined by stable 
surface markers expression and distinct phenotypes (58, 59). It is important to consider the possible 
Figure 5. GSC subpopulations vary in their self-renewal potential. Frequency of clonogenic cells was assessed by extreme limiting dilution analysis using 
GSC subpopulations derived from (A) TS667, (B) 0308, and (C) MGG8 lines (120, 60, 24, 5, and 1 cells per well; 12–18 replicates per dilution). The experiment 
was repeated 3 times, and results are shown as mean ± SEM. ANOVA with Tukey’s post hoc tests were used to assess the significance of differences 
between each GSC subpopulation; *P < 0.05 vs. quadruple-high. GSC, glioblastoma stem cell.
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effects of  media conditions, secreted factors, and the tumor microenvironment on this plasticity. Another 
point worth noting is that our experimental design did not put “unsorted” cells through the process of  
flow cytometry, and we cannot rule out that the intervention of  flow cytometry did not enhance in vivo 
tumorigenicity of  sorted cells.
From the 6 pathways studied, WNT/β-catenin and NF-κB were the main pathways associated with GSC iden-
tity. All GSC subpopulations from fresh tumor samples had more activation of  WNT/β-catenin signaling 
(indicated by non–phospho-β-catenin) than non-GSC components of  the tumor, suggesting that activation 
of  this pathway may be a distinct feature of  GSCs. β-Catenin–mediated transcriptional activity is required 
Figure 6. Mass cytometry detects core signaling within single cells among 13 GSC subpopulations from 3 patient-derived lines in long-term culture. 
Violin plots indicate protein levels for 6 intracellular pathways (pAKT, pERK, pSTAT3, non–phospho-β-catenin, pP65, and pP38) in (A) TS667, (B) 0308, 
and (C) MGG8 cells. Bottom panels show the levels (high, black; low, gray) of the cell-surface markers defining each subpopulation. Arrows highlight the 
subpopulation with the highest average protein abundance, as discussed in the text. GSC, glioblastoma stem cell.
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for self-renewal frequency through interaction with the transcription factor TCF7L2 and disruption of  this 
interaction reduces tumor volume of  subcutaneous GSC xenografts (60). Among GSCs, the quadruple 
high, CD15hiCD44hiCD133hiα6 integrin
hi cells, had the greatest activation (Figure 3A), which may explain 
their increased self-renewal capacity in vitro and increased in vivo tumorigenic capacity. These data cor-
roborate that in previous work that demonstrated that accumulation of  active non–phospho-β-catenin due 
to WNT stimulation contributes to differentiation arrest and maintenance of  the self-renewal capacity in 
mouse neural stem cells and malignant glioma patient samples (31). Recent findings suggest that instead of  
a subpopulation hierarchy, GSCs are capable of  transiting between GSC states (58). Although there might 
not be a unipotent and irreversible subpopulation, the increased clonogenicity together with increased in 
vitro and ex vivo WNT activation in the quadruple-high GSC suggest that the degree of  plasticity might be 
associated with WNT signaling and tumorigenic potential.
In vivo limiting dilution tumor formation assays have demonstrated that CD133-positive tumor 
cells are highly tumorigenic in brains of  immunocompromised mice, whereas CD133-negative cells sel-
dom form detectable tumors (7, 61). However, our work and previous results (10–15) suggest that not all 
CD133-containing populations have increased clonogenicity. In fact, our work, although not testing in 
vivo limiting dilutions, suggests that quadruple-high GSCs had the highest clonogenic renewal. This is 
consistent with the finding that decreased activation of  WNT/β-catenin pathway inhibits proliferation 
and GBM sphere formation (62).
Our findings also reveal NF-κB activation in GSCs in vivo. We observed increased phosphorylation of  
the NF-κB subunit, P65, in GSCs from all 6 patients, compared with cells devoid of  the 4 surface markers. 
NF-κB is activated in many human tumors, including glioma (63). In GSCs, the phosphorylation of  P65 
is increased due to overexpression of  the A20 protein (TNFAIP3), a mediator of  the NF-κB pathway and 
cell survival (64), and GSCs in culture have increased phosphorylation and nuclear localization of  P65, 
with resultant increased expression of  NF-κB–regulated genes (65) and associated therapeutic resistance 
(33). Inhibition of  P65 phosphorylation in combination with TMZ increases GBM cell apoptosis in vitro 
Figure 7. GSC subpopulations with increased activation of PI3K/AKT, WNT/β-catenin, NF-κB, and MAPK/P38 core 
signaling pathways have increased expression of markers for cell proliferation and translation. Violin plots indicate 
protein status of markers of cell proliferation (Ki-67) and translation (p4E-BP1, pS6) by GSC subpopulation in (A) TS667, 
(B) 0308, and (C) MGG8 cells. Bottom panels show the levels (high, black; low, gray) of the cell-surface markers defining 
each subpopulation. Arrows highlight the subpopulation with the highest average protein expression, as discussed in 
the text. GSC, glioblastoma stem cell.
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compared with TMZ alone (66). The increased P65 phosphorylation we found in GSCs suggests that 
NF-κB can be used as a potential target to increase TMZ sensitivity of  the treatment-resistant GSCs.
We expected to find increased activation of  PI3K/AKT, MEK/ERK, JAK/STAT, and MAPK/P38 
pathways in cell with increased clonogenic potential. However, we found no distinguishable difference 
in expression of  pAKT, pERK, pSTAT3, and pP38 between the GSC subpopulations among the fresh 
patient specimens we studied. Our expectations were based on studies using longer term cultures of  GSCs 
in which AKT drives renewal in GSCs in vitro (67). Similarly, JAK/Stat pathway activation is required 
for in vitro proliferation and self-renewal of  patient-derived GSCs (68), whereas Stat3 inhibition decreases 
expression of  neural stem cell transcription factor, Olig2, and inhibits neurosphere formation in GSCs (68). 
We also expected patient GSCs would have P38 inactivation because inhibition of  P38 signaling maintains 
stemness of  patient-derived CD133-positive cells (34). Instead, most GSC subpopulations from patients 
2, 3, and 6 showed increased phosphorylated P38. The absence of  differences in these pathways in fresh 
patient specimens was at odds with what we observed in our 2 long-term cultures. Larger numbers of  fresh 
specimens will add more clarity to these observations; however, these findings may highlight the differences 
between cells in situ and in culture.
Intracellular neural stem cell–associated proteins were expressed in GSC and non-GSC cells. Sox2, Musashi-1, 
Nestin, and Nanog have been considered intracellular markers of  the GSC state because of  their high 
expression in neurosphere cultures and previous reports that they are required for maintenance of  GSC 
identity (8, 20, 25, 69). In contrast, we found that the 4 intracellular markers were expressed in cells with 
and without surface markers associated with the GSC state (Figure 2). Additionally, compared with their 
quadruple-negative counterparts, not all GSC subpopulations had high levels of  expression of  all stem 
cell–associated intracellular markers (Supplemental Figure 2), suggesting that high levels of  these intra-
cellular markers are not necessarily linked to the surface marker–defined GSC state in vivo and regulate 
genes expression and signaling involved in GBM malignancy in both non-GSCs and GSCs (70). Together, 
although our study includes a small number of  patient samples, it does not support the one-to-one corre-
spondence of  high intracellular expression of  neural stem cell proteins with cell-surface expression of  GSC 
markers. However, it is possible that there exists an expression threshold of  intracellular neural stem cell 
expression that aligns more appropriately with surface marker–defined states.
Mass cytometry used to study GSC biology. This work demonstrates the utility of  mass cytometry 
to characterize GSC signaling at the single-cell level in fresh specimens and longer term cultures. 
A point worth noting is that GSCs derived from patient 4 and placed in short-term culture differed 
substantially from the GSCs present at diagnosis, in terms of  signaling and enrichment of  cell states 
with high expression of  CD133. Although this is but one example, these observations demonstrate 
that GSC identity may drift while in culture; this corroborates a bulk RNA-Seq study demonstrating 
GSCs in culture develop distinct gene expression and epigenetic profiles from their parental tumors 
(32). These differences may represent the selective pressures of  standard media, particularly with 
its high concentrations of  growth factors, glucose, and glutamine. It is worth considering this as we 
develop GSC-targeting therapies based largely on work in tissue culture or using cells from culture 
engrafted into mice. Our observation that several GSC subpopulations were present in culture that 
Figure 8. Quadruple-high GSCs are sensitive to WNT inhibition. TS667, 0308, and MGG8 GSC subpopulations were 
incubated for 5 days with the canonical WNT pathway inhibitor XAV939 and cell viability was measured. The experiment 
was repeated 3 times, and results are shown as means ± SEM. GSCs, glioblastoma stem cells.
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were not observed initially ex vivo may mean they either were present initially but below limits of  
detection or reflect that the GSC states, as defined by surface markers, are fluid.
Larger antibody panels and greater sample sizes will provide a clearer understanding of  GSC hetero-
geneity. For example, GSC subpopulations may vary at the single-cell level, in their degree of  expression 
of  commonly amplified or mutated receptors, such as EGFR and PDGFRα. Understanding oncoprotein 
expression at the single-cell level will inform our interpretation of  the failures of  targeted therapies in 
patients with brain tumors. Additionally, including antibodies specific to oncoproteins, such as EGFRvIII 
or IDH1R132H, will assist in differentiating tumor cells compared with nontransformed cells in the micro-
environment. Finally, we expect that broader mass cytometry antibody panels will identify heterogeneous 
expression of  intracellular stem cell and precursor marker expression beyond those we present here, for 
example, oligodendrocyte transcription factor 2 (71–73).
Our focus here has been on the subpopulation of  cells within the tumor that express at least one sur-
face marker associated with the GSC state. Moving forward, mass cytometry antibody panels for GBM 
that combine assessment of  GSCs, other GBM cells, and cells that compose the tumor microenvironment 
will help refine appropriate targets for therapy (74, 75). For instance, mass cytometry was recently used 
to characterize leukocyte landscapes in the environments of  primary and metastatic brain tumors (76). 
We envision an integrated approach to diagnostics and therapeutic development that includes assessing 
single-cell proteomic signaling with RNA and DNA sequencing. By applying these analytics to highly treat-
ment-resistant cells like GSCs, we will better understand the heterogeneous complexity of  GBM and how 
to best target these cells with precision.
Methods
Cell lines. GBM cancer stem cell line 0308 was provided by Howard Fine (Department of  Neurology, 
Weill Cornell Medicine, New York, New York, USA) (37, 77). TS667 from a patient with primary GBM 
was derived in-house (78), as was MGG8 from a patient with primary GBM (79). 0308 and TS667 
cells were cultured in Neurobasal media (Life Technologies) supplemented with 0.5× B27 without vita-
min A (Thermo Fisher), 0.5× N2 supplement (Thermo Fischer), 2 mM L-glutamine (Thermo Fisher), 1 
mM sodium pyruvate (Thermo Fisher), 50 μg/ml EGF (Peprotec), and 50 μg/ml basic FGF (Peprotec). 
MGG8 cells were cultured in Neurobasal media (Life Technologies) supplemented with 1× B27 without 
vitamin A, 1× N2 supplement, 3 mM GlutaMAX (Gibco), 5 mg/ml heparin (Stem Cell Technologies), 
20 ng/ml EGF (Peprotec), and 20 μg/ml basic FGF (Peprotec).
Flow cytometry analysis and clonogenic assay. 106 cells were stained with CD133-APC (4 μl/106 cells, 
TMP4, Invitrogen), CD44-Alexa Fluor 700 (2 μl/106 cells, BJ18, Biolegend), CD15-FITC (2 μl/106 
cells, HI98, Biolegend), and α6 integrin-Brilliant Violet 421 (2 μl/10
6 cells, GoH3, Biolegend) for 15 
minutes on ice. Fluorescence-minus-one controls were used. Positive and negative populations were 
gated according to Supplemental Figure 3. All cell analyses and sorting were performed on a FACS 
Aria II (BD Biosciences). For the clonogenic assay, we plated 120, 24, 5, and 1 cells per well; 12–18 
replicates per dilution in ultralow attachment surface plates. Clonogenic cell frequency was analyzed 
Figure 9. The quadruple-high subpopulation has increased in vivo tumorigenicity. 500 cells of each indicated GSC 
subpopulation of MGG8 were implanted in NCG mice (n = 6). Log-rank test was used to assess the significance of dif-
ferences between each GSC subpopulation; *P < 0.05 vs quadruple-high cells. GSC, glioblastoma stem cell.
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using ELDA (http://bioinf.wehi.edu.au/software/elda/) (39). GSC subpopulation clonogenic frequen-
cies were analyzed with 1-way ANOVA with Tukey’s post hoc test.
Cell viability. Five hundred cells of  each GSC subpopulation studied were plated in 96-well plates in 
triplicates. Cells were treated with increasing concentrations of  XAV939 (0.03, 0.1, 0.3, 1, 3, 10, 50 μM; 
Selleckchem, catalog S1180). Cell viability was measured using CellTiter-Glo (Promega, catalog G7572) 
after 5 days incubation at 37oC. All data were normalized to day 0 and expressed as a relative cell number.
Patient samples. Fresh GBM specimens were obtained from freshly resected, excess surgical material 
from patients at Barnes-Jewish Hospital.
Tumor dissociation. Fresh tumor samples were dissociated using Brain Tumor Dissociation Kit (Miltenyi 
Biotec, catalog 130-095-942) followed by treatment with Myelin Removal Beads II (Miltenyi Biotec, cata-
log 130-096-733) and Debris Removal Solution (Miltenyi, catalog 130-109-38), according to manufacturer’s 
instruction. Cells were counted and immediately labeled for mass cytometry analysis.
Mass cytometry staining and analysis. 3 × 106 cells from GSC lines or from patient samples were stained 
for mass cytometry as described previously (80) using a panel of  20 antibodies (Table 1) and cisplatin to 
identify dead cells (81). GSCs were differentiated with 10% FBS in DMEM for 6 weeks as negative controls 
for cell-surface markers. These cells were run alongside the GSCs. Individual sample read-outs were record-
ed on a CyTOF2 mass cytometer (Fluidigm). At least 2.5 × 105 events were recorded for each sample and 
uploaded to Cytobank (http://cytobank.org) (82) for subsequent analysis.
Mice and tumor implantation. Human GBM cells (MGG8) were grown in Neurobasal media with sup-
plements as described above. Cells were harvested and dissociated with Accumax (Innovative Cell Technol-
ogies) then washed and resuspended in fresh media. GSC subpopulations expressing a single GSC cell-sur-
face marker were enriched using LD columns (Miltenyi Biotec), according to manufacturer’s instruction. 
For each GSC subpopulation, 30 × 106 cells were incubated with stem cell surface antibody minus the 
corresponding highly expressed marker. GSCs were incubated on ice for 15 minutes with CD133-APC (4 
μl/106 cells, TMP4, Invitrogen), CD44-Alexa Fluor 700 (2 μl/106 cells, BJ18, Biolegend), CD15-Brilliant 
Violet 605 (2 μl/106 cells, HI98, Biolegend), and α6 integrin-Brilliant Violet 421 (2 μl/10
6 cells, GoH3, 
Biolegend). After enrichment, GSCs were labeled with the corresponding missing antibody, sorted for the 
single markers, and immediately implanted.
A total of  500 cells per animal were implanted into 6-week-old NCG female mice (NOD-Prkdcem26Cd52Il-
2rgem26Cd22/NjuCrl; Charles River Laboratory). Briefly, animals were anesthetized by intraperitoneal injection 
of  ketamine (10 mg/kg) and placed in a stereotactic apparatus (Stoelting). An incision was made over the 
cranial midline and a burr hole was made 1.5 mm anterior to the lambda and 2.5 mm right of  the midline. A 
29.5-gauge Hamilton syringe was inserted to a depth of  3 mm and withdrawn 0.5 mm to a depth of  2.5 mm. 
MGG8 cells (3 μl) were injected over the course of  5 minutes. The incision site was closed by Vetbond (3M).
Animal monitoring. Mice were monitored for status daily and sacrificed when neurological deficits 
became significant.
Statistics. All grouped data are presented as mean ± SEM as indicated. All statistical analyses were 
performed using R version 3.5.0 (R Foundation for Statistical Computing) and the tidyverse library (R 
package version 1.2.1). Supplemental analysis was performed using Prism 7.0 software (GraphPad). 
ANOVA with Tukey’s post hoc test was used to assess the significance of  differences between each GSC 
subpopulation in clonogenic assay. Kruskal-Wallis with Mann-Whitney post hoc test was used to assess 
the significance of  non-phospho-β-catenin and pP65 between GSCs and cells with low expression of  
surface markers. Kruskal-Wallis with Bonferroni’s post hoc tests were used to assess the significance of  
differences between GSCs grouped by the number of  highly expressed surface markers of  non–phos-
pho-β-catenin. For animal survival analysis, Kaplan-Meier curves were generated, and log-rank (Man-
tel-Cox) test was performed to assess difference relative to quadruple-high cells. A P value of  less than 
0.05 was considered significant.
Study approval. Approval for the use of  human subject material after informed consent was granted 
by the Institutional Review Board of  Washington University School of  Medicine in accordance with IRB 
protocol 201111001. Animal studies were performed in accordance with the recommendations in the Guide 
for the Care and Use of  Laboratory Animals (National Academies Press, 2011). The protocols were approved 
by the Institutional Animal Care and Use Committee at the Washington University School of  Medicine 
(assurance no. A338101). Inoculations were performed under anesthesia induced and maintained with 
ketamine hydrochloride and xylazine, and all efforts were made to minimize animal suffering.
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